Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exjade in β-thalassemia with severe cardiac iron overload
NCT01459718Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox in beta thalassemia, iron overload cardiomyopathy (IOC), sponsored by Novartis. Started Jan 2011; status: terminated.
02
Drugs
deferasirox
03
Conditions
beta thalassemiairon overload cardiomyopathy (IOC)
Beyond the preview
Go deeper on NCT01459718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01459718.